Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies
Abstract Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti‐HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abno...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.1879 |
id |
doaj-40e9a77e561148afa8859397e1b7d125 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dominique Rosillon Laurence Baril Maria Rowena Del Rosario‐Raymundo Cosette Marie Wheeler Susan Rachel Skinner Suzanne Marie Garland Jorge Salmeron Eduardo Lazcano‐Ponce Carlos Santiago Vallejos Tanya Stoney Bram ter Harmsel Timothy Yong Kuei Lim Swee Chong Quek Galina Minkina Shelly Ann McNeil Celine Bouchard Kah Leng Fong Deborah Money Arunachalam Ilancheran Alevtina Savicheva Margaret Cruickshank Archana Chatterjee Alison Fiander Mark Martens Marie Cecile Bozonnat Frank Struyf Gary Dubin Xavier Castellsagué |
spellingShingle |
Dominique Rosillon Laurence Baril Maria Rowena Del Rosario‐Raymundo Cosette Marie Wheeler Susan Rachel Skinner Suzanne Marie Garland Jorge Salmeron Eduardo Lazcano‐Ponce Carlos Santiago Vallejos Tanya Stoney Bram ter Harmsel Timothy Yong Kuei Lim Swee Chong Quek Galina Minkina Shelly Ann McNeil Celine Bouchard Kah Leng Fong Deborah Money Arunachalam Ilancheran Alevtina Savicheva Margaret Cruickshank Archana Chatterjee Alison Fiander Mark Martens Marie Cecile Bozonnat Frank Struyf Gary Dubin Xavier Castellsagué Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies Cancer Medicine human papillomavirus infection naturally acquired antibodies redetection or reactivation of HPV infection cervical abnormality risk reduction |
author_facet |
Dominique Rosillon Laurence Baril Maria Rowena Del Rosario‐Raymundo Cosette Marie Wheeler Susan Rachel Skinner Suzanne Marie Garland Jorge Salmeron Eduardo Lazcano‐Ponce Carlos Santiago Vallejos Tanya Stoney Bram ter Harmsel Timothy Yong Kuei Lim Swee Chong Quek Galina Minkina Shelly Ann McNeil Celine Bouchard Kah Leng Fong Deborah Money Arunachalam Ilancheran Alevtina Savicheva Margaret Cruickshank Archana Chatterjee Alison Fiander Mark Martens Marie Cecile Bozonnat Frank Struyf Gary Dubin Xavier Castellsagué |
author_sort |
Dominique Rosillon |
title |
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies |
title_short |
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies |
title_full |
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies |
title_fullStr |
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies |
title_full_unstemmed |
Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies |
title_sort |
risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired hpv‐16/18 antibodies |
publisher |
Wiley |
series |
Cancer Medicine |
issn |
2045-7634 |
publishDate |
2019-08-01 |
description |
Abstract Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti‐HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. Methods Serum anti‐HPV‐16/18 antibodies were determined at baseline and every 12 months in baseline DNA‐negative women (N = 2687 for HPV‐16 and 2705 for HPV‐18) by enzyme‐linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6‐months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7‐year period. The association between the risk of type‐specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models. Results Risk of newly detected HPV‐16‐associated 6‐month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC‐US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV‐16‐associated incident infections (HR = 0.81 [0.56; 1.16]) and 12‐month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV‐18‐seropositive vs ‐seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6‐month PIs, HR = 0.31 [0.07; 1.36] for 12‐month PIs, and HR = 0.61 [0.23; 1.61] for ASC‐US+). Conclusions Naturally acquired anti‐HPV‐16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15‐ to 25‐year‐old women. |
topic |
human papillomavirus infection naturally acquired antibodies redetection or reactivation of HPV infection cervical abnormality risk reduction |
url |
https://doi.org/10.1002/cam4.1879 |
work_keys_str_mv |
AT dominiquerosillon riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT laurencebaril riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT mariarowenadelrosarioraymundo riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT cosettemariewheeler riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT susanrachelskinner riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT suzannemariegarland riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT jorgesalmeron riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT eduardolazcanoponce riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT carlossantiagovallejos riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT tanyastoney riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT bramterharmsel riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT timothyyongkueilim riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT sweechongquek riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT galinaminkina riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT shellyannmcneil riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT celinebouchard riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT kahlengfong riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT deborahmoney riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT arunachalamilancheran riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT alevtinasavicheva riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT margaretcruickshank riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT archanachatterjee riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT alisonfiander riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT markmartens riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT mariececilebozonnat riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT frankstruyf riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT garydubin riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies AT xaviercastellsague riskofnewlydetectedinfectionsandcervicalabnormalitiesinadultwomenseropositiveorseronegativefornaturallyacquiredhpv1618antibodies |
_version_ |
1725973157319278592 |
spelling |
doaj-40e9a77e561148afa8859397e1b7d1252020-11-24T21:27:49ZengWileyCancer Medicine2045-76342019-08-018104938495310.1002/cam4.1879Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodiesDominique Rosillon0Laurence Baril1Maria Rowena Del Rosario‐Raymundo2Cosette Marie Wheeler3Susan Rachel Skinner4Suzanne Marie Garland5Jorge Salmeron6Eduardo Lazcano‐Ponce7Carlos Santiago Vallejos8Tanya Stoney9Bram ter Harmsel10Timothy Yong Kuei Lim11Swee Chong Quek12Galina Minkina13Shelly Ann McNeil14Celine Bouchard15Kah Leng Fong16Deborah Money17Arunachalam Ilancheran18Alevtina Savicheva19Margaret Cruickshank20Archana Chatterjee21Alison Fiander22Mark Martens23Marie Cecile Bozonnat24Frank Struyf25Gary Dubin26Xavier Castellsagué27GSK Wavre BelgiumGSK Wavre BelgiumDepartment of Obstetrics and Gynecology San Pablo Colleges Medical Center San Pablo City The PhilippinesUniversity of New Mexico Health Sciences Center Albuquerque New MexicoVaccines Trials Group Telethon Kids Institute Perth Western Australia AustraliaThe Royal Women's Hospital, The Royal Children's Hospital, Murdoch Childrens Research Institute University of Melbourne Parkville Victoria AustraliaInstituto Mexicano del Seguro Social Morelos MexicoNational Institute of Public Health Cuernavaca MexicoDepartamento de Oncología Médica Oncosalud‐AUNA Lima PeruTelethon Kids Institute University of Western Australia Perth Western Australia AustraliaDepartment of Gynecology Roosevelt Kliniek, Leiden Delft The NetherlandsKK Hospital Singapore City SingaporeASC Clinic for Women Gleneagles Hospital Singapore City SingaporeCity Clinical Hospital Moscow RussiaCanadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority Dalhousie University Halifax Nova Scotia CanadaClinique de Recherche en Santé des Femmes Québec City Québec CanadaSingapore General Hospital Singapore City SingaporeThe Women's Health Research Institute University of British Columbia Vancouver British Columbia CanadaDivision of Gynaecologic Oncology, Department of Obstetrics and Gynaecology National University Hospital Singapore City SingaporeLaboratory of Microbiology DO Ott Research Institute of Obstetrics, Gynaecology and Reproductology St. Petersburg RussiaDepartment of Obstetrics and Gynaecology, Aberdeen Maternity Hospital NHS Grampian Scotland, UKDepartment of Pediatrics University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic Sioux Falls South DakotaLeading Safe Choices Programme Royal College of Obstetricians and Gynaecologists London UKReading Hospital Pennsylvania4Clinics Paris FranceGSK Wavre BelgiumGSK King of Prussia PennsylvaniaInstitut Català d'Oncologia (ICO) IDIBELL, CIBER‐ESP, L'Hospitalet de Llobregat Catalonia SpainAbstract Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti‐HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. Methods Serum anti‐HPV‐16/18 antibodies were determined at baseline and every 12 months in baseline DNA‐negative women (N = 2687 for HPV‐16 and 2705 for HPV‐18) by enzyme‐linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6‐months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7‐year period. The association between the risk of type‐specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models. Results Risk of newly detected HPV‐16‐associated 6‐month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC‐US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV‐16‐associated incident infections (HR = 0.81 [0.56; 1.16]) and 12‐month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV‐18‐seropositive vs ‐seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6‐month PIs, HR = 0.31 [0.07; 1.36] for 12‐month PIs, and HR = 0.61 [0.23; 1.61] for ASC‐US+). Conclusions Naturally acquired anti‐HPV‐16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15‐ to 25‐year‐old women.https://doi.org/10.1002/cam4.1879human papillomavirus infectionnaturally acquired antibodiesredetection or reactivation of HPV infectioncervical abnormalityrisk reduction |